Compare iShares Core Growth Allocation ETF (AOR) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs 22nd Century Group Inc — how do they compare? iShares Core Growth Allocation ETF trades at $70.09, while 22nd Century Group Inc trades at $4.38 (market cap $1.52M). The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| AOR | XXII | |
|---|---|---|
52-Week High | $70.12 | $801.00 |
52-Week Low | $62.26 | $3.72 |
Market Cap | — | $1.52M |
Sector | — | Technology |
Enterprise Value | — | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, an iShares Core Growth Allocation ETF, trades at $70.11, up 0.27% today. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF maintains a fixed 60/40 stock/bond allocation and rebalances semiannually with a low 0.20% fee. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
The ETF offers diversified exposure but faces risks from equity-bond correlation shifts and competition from pure equity funds. Analyst sentiment is mixed, balancing its simplicity against historical lagging returns. Key catalysts include fee waivers until December 2026 and semiannual rebalancing, but investors should weigh its conservative allocation against growth objectives.
XXII trades at $4.46, up 2.53% today, with a neutral technical signal and bearish moving averages. The company shows deep losses with a net income margin of -65.76% and negative ROE of -130.19%, though it beat earnings in Q3 2025. Recent news highlights VLN® retail expansion in California and New York, and a reverse stock split on June 12, 2026. Cash flow remains dependent on financing, with operating cash flow negative at -$7.72 million in 2025.
Outlook is speculative; analyst consensus is 75% buy with growth potential from VLN® market expansion, but high execution and regulatory risks persist. Investment hinges on revenue scaling to offset persistent losses, with stock volatility expected near key resistance at $5.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
